The authors have reported to CHEST errors in Table 1 in their article, “Tracheobronchopathy From Inhaled Corticosteroids” (Chest. 2017;152[6]:1296-1305).
-
•
The table title should have reflected that the table’s intent was not to provide strict dose equivalence but to act as a guide for prescribing physicians to highlight what should be considered a “high-dose” inhaled corticosteroid.
-
•
There were errors in doses for beclometasone dipropionate, budesonide, mometasone furoate, and triamcinolone acetonide.
The corrected table appears below. The online article has been corrected.
Table 1.
Corticosteroids for Adults: Estimated Clinical Comparability (μg)a
| Inhaled Corticosteroid | Low | Medium | High |
|---|---|---|---|
| Beclometasone dipropionate (HFA) | 100-200 | >200-400 | >400 |
| Budesonide (DPI) | 200-400 | >400-800 | >800 |
| Ciclesonide (HFA) | 80-160 | >160-320 | >320 |
| Flunisolideb | 80-160 | >160-320 | >320 |
| Fluticasone furoate (DPI) | 100 | NA | 200 |
| Fluticasone propionate (DPI) | 100-250 | >250-500 | >500 |
| Fluticasone propionate (HFA) | 100-250 | >250-500 | >500 |
| Mometasone furoate | 110-220 | >220-440 | >440 |
| Triamcinolone acetonide | 400-1,000 | >1,000-2,000 | >2,000 |
DPI = dry powder inhaler; HFA = hydrofluoroalkane propellant; NA = not available.
Modified from Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2017. https://ginasthma.org/wp-content/uploads/2016/01/wms-GINA-2017-main-report-tracked-changes-for-archive.pdf.
Linezolid inhaler has been used as a stand-alone inhaled corticosteroid in the past with varying doses for patients with asthma. Higher doses as indicated in this chart may contribute to bronchopathy described in this article, and the aim is to bring this issue to light for patients who may have already been exposed previously.